Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy.
antiretroviral agents
human immunodeficiency virus
protease inhibitors
residual viremia
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
21 02 2020
21 02 2020
Historique:
received:
18
09
2019
accepted:
05
12
2019
pubmed:
11
12
2019
medline:
22
12
2020
entrez:
11
12
2019
Statut:
epublish
Résumé
HIV persistence despite therapy contributes to chronic immune activation and inflammation, increasing the risk of aging-associated events in HIV-infected individuals. We sought here to better understand the complex link between clinical and treatment features and HIV persistence despite therapy. A total of 11,045 samples from 1,160 individuals under combination antiretroviral therapy (cART) with an unquantifiable viral load (VL; limit of quantification, 20 copies/ml) were categorized as detectable or undetectable depending on the detection of a PCR signal using a commercially available assay. Generalized estimating equation (GEE) regression was used to model viral load detectability and to assess the determinants of residual viremia (RV; VL detected below 20 copies/ml) despite therapy. A high VL zenith was associated with a higher probability to have a detectable viremia under cART. Conversely, the probability to have a detectable viral load below 20 copies/ml decreased with time under therapy. Of therapy regimens, protease inhibitor (PI)-based cART was associated with a significantly higher probability of detectable RV compared to nonnucleoside transcriptase inhibitor- or integrase inhibitor-based cART. We found that a PI-based treatment regimen is highly associated with an increased frequency of RV, supporting previous evidence suggesting that PI-based cART regimens could favor ongoing viral replication in some individuals.
Identifiants
pubmed: 31818822
pii: AAC.01902-19
doi: 10.1128/AAC.01902-19
pmc: PMC7038286
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
HIV Protease Inhibitors
0
Reverse Transcriptase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
AIDS. 2015 Aug 24;29(13):1665-71
pubmed: 26372277
Antimicrob Agents Chemother. 2009 Jun;53(6):2367-74
pubmed: 19307360
Clin Infect Dis. 2015 Feb 15;60(4):627-38
pubmed: 25362204
J Clin Microbiol. 2014 Nov;52(11):3944-51
pubmed: 25187636
Nat Med. 2016 Aug;22(8):839-50
pubmed: 27400264
Curr Top Microbiol Immunol. 2018;417:1-22
pubmed: 29071474
J Infect Dis. 2013 Nov 1;208(9):1436-42
pubmed: 23975885
Immunol Rev. 2013 Jul;254(1):78-101
pubmed: 23772616
Clin Microbiol Rev. 2016 Oct;29(4):859-80
pubmed: 27559075
PLoS One. 2009 Dec 31;4(12):e8490
pubmed: 20046870
PLoS One. 2017 Oct 19;12(10):e0185761
pubmed: 29049344
AIDS. 2014 Jan 14;28(2):181-186
pubmed: 24361679
Open Forum Infect Dis. 2019 Apr 10;6(5):ofz177
pubmed: 31123690
Front Immunol. 2018 Feb 19;9:260
pubmed: 29515578
Lancet HIV. 2017 Aug;4(8):e328-e329
pubmed: 28750742
Clin Infect Dis. 2019 Sep 27;69(8):1320-1328
pubmed: 30590412
Immunol Rev. 2013 Jul;254(1):326-42
pubmed: 23772629
Top Antivir Med. 2013 Sep-Oct;21(4):128-32
pubmed: 24225078
J Med Virol. 2009 Mar;81(3):400-5
pubmed: 19152404
Biochem Pharmacol. 2017 Dec 15;146:10-22
pubmed: 28687465
J Virol. 2014 Sep 1;88(17):10056-65
pubmed: 24965451
PLoS One. 2012;7(7):e41390
pubmed: 22848481
Top Antivir Med. 2014 Jun-Jul;22(3):660-5
pubmed: 25101532
J Antimicrob Chemother. 2014 Mar;69(3):753-6
pubmed: 24187041
J Infect Dis. 2012 Nov;206(9):1443-52
pubmed: 22927449
Clin Epigenetics. 2016 Feb 19;8:19
pubmed: 26900410
PLoS One. 2015 Oct 15;10(10):e0140791
pubmed: 26468956
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12
pubmed: 24469825
Curr Opin HIV AIDS. 2016 Mar;11(2):234-41
pubmed: 26575148
AIDS. 2013 Aug 24;27(13):2019-29
pubmed: 24201117
Int J Antimicrob Agents. 2018 Oct;52(4):492-499
pubmed: 30009958
Clin Infect Dis. 2012 Mar 1;54(5):724-32
pubmed: 22238167
Trends Immunol. 2017 Mar;38(3):217-228
pubmed: 28073694
Nature. 2016 Feb 4;530(7588):51-56
pubmed: 26814962
Nat Med. 2010 Apr;16(4):460-5
pubmed: 20228817
Lancet. 2013 Nov 2;382(9903):1525-33
pubmed: 24152939
Nature. 2011 Aug 17;477(7362):95-8
pubmed: 21849975
AIDS. 2011 Jan 28;25(3):341-4
pubmed: 21157295
Curr Opin Infect Dis. 2012 Feb;25(1):17-25
pubmed: 22156900
Immunity. 2013 Oct 17;39(4):633-45
pubmed: 24138880
AIDS. 2009 Oct 23;23(16):2165-71
pubmed: 19657270
Nat Immunol. 2015 Jun;16(6):584-9
pubmed: 25990814
J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):129-34
pubmed: 23018379